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The workshop on “New approaches to investigate drug-induced hypersensitivity” was held on June 5 2014 at the Foresight centre, University of Liverpool. The aims of the workshop were to (1) discuss our current understanding of the genetic, clinical and chemical basis of small molecule drug hypersensitivity (2) highlight the current status of assays that might be developed to predict potential drug immunogenicity, (3) identify the limitations, knowledge gaps and challenges that limit the use of these assays and utilise the knowledge gained from the workshop to develop a pathway to establish new and improved assays that better predict drug-induced hypersensitivity reactions during the early stages of drug development. This perspective article reviews the clinical and immunological bases of drug hypersensitivity and summarises various experts’ views on the different topics covered during the meeting. 





Drug hypersensitivity reactions (DHRs) are rare, complex, mostly unpredictable and potentially fatal. These reactions are often immune-mediated, resulting in patient morbidity, ineffective drug therapy, drug attrition and/or drug withdrawal. Although they are rare, it is important to predict these reactions at the early stages of drug research and development. Early prediction of the potential of new drugs and/or their metabolite(s) to cause hypersensitivity will not only significantly reduce the rate of drug attrition in the pharmaceutical industry but will greatly enhance the therapeutic use of drugs in clinical settings. Multiple factors are critical to the development of DHRs; these include: the drug antigen, environmental factors and most importantly, patient-specific factors. These factors can be viewed as “the TRIANGLE of susceptibility to drug hypersensitivity”. Thus, Drug hypersensitivity = f [drug + patient genotype + patient phenotype]. A clear insight into the relative contributions of each of these factors is important in clinical diagnosis but also for the development of novel systems to predict the immunogenicity of a candidate drug. Characterization of the molecular pathophysiological mechanism(s) of drug hypersensitivity using a combination of in vitro assays and animal models is a critical step towards designing assays that will accurately predict which new drug will cause these reactions before they become widely used as therapeutics.
Unexpected but potentially fatal DHRs are among the most important reasons why drugs have failed at advanced stages of research and development.1 These reactions constitute approximately 14% of adverse drug reactions (ADRs) with symptoms ranging from mild rash to more severe clinical manifestations such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and idiosyncratic drug-induced liver injury (DILI). ADDIN EN.CITE 2-5 Although the risk factors of DHR have been well studied, their relative contributions are still poorly understood. Complications are also inherent in capturing the contributions of co-morbidities and co-medications in a particular case of DHR. 
During the early stages of drug development, an enormous amount of information regarding the chemistry, efficacy, pharmacokinetics and pharmacodynamics of a candidate drug is available to researchers/scientists. Also available at this stage is an in-depth understanding of the disease pathogenesis, risk factors, co-morbidities, and diagnostic and prognostic biomarkers. In contrast, very little is known about the genetic (epigenetic and nucleotide polymorphism) and non-genetic peculiarities of the potential patient(s) for whom the given drug is being designed. The difficulty to fully predict DHRs during the preclinical stages of drug development may partially be related to the fact that safety studies are usually performed in young, healthy animals. Although high throughput assays exist to evaluate potentially toxic molecules based on in vitro covalent binding, ADDIN EN.CITE 6 these assays alone are inadequate to predict the potential of a candidate drug and/or its metabolite(s) to induce DHRs. Hence, there is a need to develop assays that can integrate the various risk factors and enhance predictability of drug hypersensitivity.
Drug hypersensitivity can be defined as a serious ADR often with an immunological aetiology to an otherwise safe and effective therapeutic agent. Of note, the definition is used to describe reactions targeting skin and internal organs that manifest in a typically very small percentage of individuals exposed to a therapeutic drug. The frequency and severity of drug hypersensitivity are variable, increasing with disease and dose. Hence, it is important to understand the biology of the patient/immune system, the pathophysiology of the disease in question and the chemistry of the drug antigen. There are multiple mechanisms by which a drug may act as an antigen or immunogen to activate the immune system, and induce targeted tissue damage. The hapten, the pharmacological interaction with immune receptors and the altered self-peptide hypotheses go some way to explain the molecular pathomechanisms underlying DHRs. These running hypotheses define and characterise the different aspects of the drug antigen such as haptenicity, antigenicity, immunogenicity and hypersensitivity. Haptens are defined as low molecular weight chemicals with the propensity to bind covalently to protein. In the context of this review, the term antigen is used to describe a drug-related substance that interacts specifically with immunological receptors such as antibodies or T-cell receptors. Finally, immunogens are molecules capable of stimulating a cellular and/or humoral immune response. 
Also important is a clear understanding of the co-stimulatory signals (signal two) that augment the antigenic signal (signal one). Co-stimulatory signals can be either biological (infections) or mechanical (irritants and contact allergen), that provide danger signals (PAMPS-pathogen associated molecular patterns; DAMPS-damage associated molecular patterns, ROS-reactive oxygen species and ATP-adenosine triphosphate) capable of immune activation. Similar to the co-stimulatory molecules, the role of co-inhibitory checkpoint molecules such as PD-1 (Programmed Death 1 receptor), ADDIN EN.CITE , CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4) ADDIN EN.CITE 9, LAG3 (Lymphocyte Activation Gene-3) ADDIN EN.CITE 10 and TIM-3 (T-cell Immunoglobulin domain and Mucin domain 3) ADDIN EN.CITE 11 in the regulation of the immune system have been extensively researched. However, their importance in regulating drug antigen-specific T-cell responses in tolerant patients has not been studied. The evolution of pharmacogenetics has provided in-depth insights into individual susceptibility to various DHRs, and represents an important milestone towards stratified/precision medicine. Expression of specific HLA alleles is now known to be a major determinant of whether drug exposure will result in an inadvertent immune response and tissue injury. In fact, pre-prescription genotyping of patients for the risk allele HLA-B*57:01 prior to administration of abacavir has significantly reduced the incidence of hypersensitivity reactions. ADDIN EN.CITE , This concept has also been recommended for HLA-B*15:02 (Chinese) and HLA-A*31:01 (Caucasians) before carbamazepine prescription. ADDIN EN.CITE , However, prediction of DHRs in the clinic, based solely on HLA-genotype, remains very limited. This is because the majority of individuals who carry known HLA risk alleles do not develop immunological reactions when exposed to a culprit drug. We must therefore assume that immunological parameters, other than HLA genotype, may also contribute to the development of a drug-specific T-cell response. Since susceptibility to drug hypersensitivity is a function of the patient’s individual biology, the prediction of drug hypersensitivity will involve capturing the patient’s biology and variability during the early stages of drug development within pre-clinical test systems.
This workshop, hosted by the CDSS (Centre for Drug Safety Science) in conjunction with the ABPI (Association of British Pharmaceutical Industry) and MHRA (The Medicines and Healthcare Products Regulatory Agency) provided the framework for speakers to discuss the current status of drug hypersensitivity research. Speakers and delegates were also encouraged to identify areas of deficiency and offer recommendations for future research strategies.

The key questions for consideration during and after the workshop included:
1. Which current in vitro endpoints are fit for the purpose of diagnosing drug hypersensitivity in humans?
2. Is there an animal model that can be used to determine the potential of a drug to produce hypersensitivity reactions in humans? If so, how can we validate such a model?
3. What predictive in vitro assays show the most promise at this time and what types of in vitro assays should be developed in the future?
4. Can assays discriminate between drugs which produce reactions at a higher incidence (>5-10%) or at a lower incidence (<0.01%)? 
5. Is the evaluation of drug-antigen formation a useful approach? If yes, what type of approach should be used? If no, why is this approach not useful?
6. Do drugs with the potential to elicit hypersensitivity reactions have particular chemical or pharmacological properties in common?





THE VIEWPOINT FROM INDUSTRY
Hypersensitivity issues faced by industry during drug development
Jessica Whritenour (Pfizer) opened the meeting by providing an industry perspective on the impact of DHRs in drug development. She highlighted potential issues faced by pharmaceutical companies during the different stages of drug development and the impacts of these challenges.  Although the potential issues related to DHRs could be different depending on the development phase, the lack of predictive and diagnostic tools to aid in the identification and management of the risk is a common gap at all stages of drug development.  For example, during nonclinical development, predictive tools are not available for prospective risk assessment to identify molecules that, based on chemical structure, may have the potential to cause DHRs.  If a DHR is observed during toxicity studies (rare), tools are not routinely available to investigate the mechanism for the observed reaction in the toxicity species or to screen/de-risk back-up compounds to try and identify a compound without a potential DHR liability.  As a compound moves into early clinical development, a potential issue that may be encountered is the occurrence of mild skin rash in a relatively high percentage of patients. In this case, understanding the mechanism for the reactions (allergic or non-allergic), whether the reactions will increase in severity with longer duration of treatment, and whether the reactions will be observed in phase II/III studies at doses that did not produce reactions in phase I studies are important considerations in risk management.  
During phase III/commercialisation, a potential issue that currently is impossible to predict is the rare but severe reaction without an identifiable risk factor. When such an issue is encountered, diagnosis and confirmation that the reaction is related to the study drug are key considerations for managing the risk and progressing with the development of the drug.  Unfortunately, there are limited (if any) tools to address the majority of these questions/concerns highlighted above.
The potential issues discussed above underscore unmet needs in this area of predictive and diagnostic drug safety science. Hence, there is an absolute need to establish novel tools to help identify and manage risks. An important issue surrounding predictive testing is the suitability of a particular assay to address a given question. For example, does the assay developed to assess the formation of reactive intermediates accurately predict the development of drug hypersensitivity? Do we need to incorporate HLA alleles into in vitro/in vivo predictive assays? What is the level of validation (i.e., the specificity and selectivity) of an assay that needs to be established, with known positive and negative controls? 

DEFINING THE CLINICAL PROBLEM
Phenotypic assessment of drug hypersensitivity and HLA alleles as genetic risk factors
Munir Pirmohamed (The University of Liverpool; director of the CDSS) gave an insight into the various definitions associated with DHRs. He stressed the importance of consistent terminology and of using the European Network on Drug Allergy’s (ENDA) definition of drug hypersensitivity. ENDA defines drug hypersensitivity as objectively reproducible symptoms or signs initiated by exposure to a drug at a dose normally tolerated by non-hypersensitive persons. Drug allergy on the other hand refers to immunologically mediated DHRs. Hence non-allergic hypersensitivity reactions are not necessarily immune-mediated. DHRs can be broadly classified into two sub-groups: (1) immediate hypersensitivity or Type I reactions that are IgE-mediated. Not much is known about any genetic predisposition to these reactions. (2) Delayed hypersensitivity reactions that are mainly Type IV reactions according to Coombs and Gell but may sometimes include Type III phenotypes.16 These reactions are T-cell-mediated and have variable clinical manifestations. The epidemiology of drug hypersensitivity is complicated by the number of drugs that cause reactions and the difficulties encountered in accurate diagnosis. Thus, a systematic approach is needed to identify how often reactions to specific drugs occur in a given population. 
The risk factors for DHRs include: high mass dose, route of administration, sex, viral infections and genetic factors. To date, approximately 25 HLA-associated ADRs have been identified (Table 1), most of them reaching genome wide significance. The discovery of strong associations between DHRs and particular HLA alleles further implicates MHC-restricted T-cell responses in disease aetiology as the primary role of the proteins encoded by HLA is to effectively present antigenic peptides to passing T-cells. The successful interaction between HLA molecule, peptide, and corresponding T-cell receptor (TCR) is referred to as the ‘immunological synapse’ and acts as signal one for the successful activation of T-cells. 17 Exactly how HLA-peptide binding mediates TCR triggering, and thus stimulation of a T-cell signalling cascade, currently remains unresolved despite the proposal of multiple models categorised as aggregation, segregation, and conformational alteration.18 The TCR interaction is sensitive and stimulation requires high avidity to antigenic HLA-(drug) peptide complexes, which are often present at very low concentrations and thus potentially difficult to detect amongst the more abundantly presented self-peptides. Such high affinity binding overcomes an activation threshold, while self-peptides provide a suboptimal response and trigger a negative feedback loop whereby the tyrosine phosphatase SHP-1 is recruited to inactivate further T-cell signalling. ADDIN EN.CITE 18-20

Table 1: HLA-associated drug hypersensitivity and target organs affected.


To account for the endless array of encountered non-self-antigens, the HLA locus is the most polymorphic locus in the human body leading to a broad range of genetic diversity. HLA alleles are subdivided into two major gene classes, defined by the type of antigen that each presents, major histocompatibility complex (MHC) class I and II. MHC class I, encoded by HLA class I alleles, is expressed on all nucleated cells and presents intracellular antigenic peptides loaded in the endoplasmic reticulum, and mostly made up of the peptide remnants of proteasome-mediated protein degradation, to CD8+T-cells. In contrast, MHC class II expression is mainly restricted to professional antigen presenting cells. As antigen-loading occurs within the endocytic pathway whereby antigens are derived from internalised proteins, MHC class II molecules present peptides derived from extracellular proteins to CD4+T-cells.  ADDIN EN.CITE 21-23 These seemingly distinct pathways overlap in a process termed cross-presentation whereby HLA class I may present extracellular antigens to allow the development of a cytotoxic T-cell response to exogenous antigens as part of the priming pathway for the eradication of tumours and viruses. Similarly, endogenous antigens may be presented on HLA class II when they traverse the secretory pathways of the cell or are produced under specific circumstances such as autophagy. ADDIN EN.CITE , When discussing the mechanisms by which drugs activate T-cells, one must consider these immunological processes in the context of therapeutic drug exposure. It is highly likely different pathways of drug antigen-specific T-cell activation occur in vitro when cells are sometimes exposed to millimolar drug concentrations. 
Both MHC class I and II are further subdivided with HLA class I consisting of HLA-A, HLA-B, and HLA-C genes as well as the less abundant non-classical HLA-E, HLA-F, and HLA-G, whilst HLA class II is made up of proteins deriving from HLA-DR, HLA-DP, and HLA-DQ genes. A third set termed MHC class III represent 57-60 non-classical HLA genes of which many do not play a direct role in antigen presentation. ADDIN EN.CITE ,
The potential for inter-individual genetic variation in the development of hypersensitivity was first indicated clinically after a pair of monozygotic twins developed carbamazepine-induced hypersensitivity, postulating some familial genetic predisposition.27 Since then, the highly polymorphic HLA locus has been associated with DHRs through the identification of numerous different HLA allele associations with T-cell responses to different drugs, in both the skin and liver. The best documented HLA association with DHRs is that of the reverse transcriptase inhibitor abacavir (ABC) and HLA-B*57:01 first reported in 2002,28 which remains the paradigm for the application of HLA genetic testing to clinical drug therapy in order to reduce the incidence of hypersensitivity. Currently, the only other drug for which administration requires the patient to be HLA-typed is carbamazepine (CBZ), a commonly prescribed antiepileptic medication which causes SJS/TEN associated with HLA-B*15:02. This genetic test is highly clinically informative, as it was found to have a 100% sensitivity, and a specificity of 97%.29
Despite this, most HLA associations with DHRs have much lower prognostic values and thus the expression of a specific HLA-allele is often not reason enough to withhold a potentially lifesaving drug. For instance, HLA-B*57:01, the allele associated with ABC-hypersensitivity, is also associated with flucloxacillin-induced DILI. However, in comparison to ABC,  just 1 in 500-1000 HLA-B*57:01+ individuals who receive flucloxacillin will develop an adverse reaction.30 Moreover, the binding of flucloxacillin-derived antigen to MHC molecules is much less stringent. Specifically, binding of flucloxacillin to closely related alleles of the B17 serological family provides antigenic determinants that activate T-cells. This does not occur with abacavir. ADDIN EN.CITE 31 Members of the B17 family including HLA-B*57:01, HLA-B*58:01, HLA-B*58:02, HLA-B*57:02, and HLA-B*57:03, share > 90% sequence homology and as such have peptide-binding repertoires which substantially overlap. ADDIN EN.CITE 32 Other HLA associations with DHRs include lumiracoxib with HLA-DRB1*15:01, and lapatinib with HLA-DRB1*07:01 which will be discussed later in this review. It is important to bear in mind that large linkage disequilibrium exists between genes in these loci, so an apparent association may in truth be related to another allele or haplotype associated with the detected allele. ADDIN EN.CITE , 
Since most individuals who express a HLA risk allele do not develop a reactions when exposed to a candidate drug, genetic, environmental or disease risk factors must impact on patient susceptibility. As drug metabolites are implicated in a number of DHRs, it is arguable that the expression of polymorphic drug metabolising enzymes may expose individuals within a population to varied quantities of antigenic moieties. Indeed, this may affect both phase I and II metabolism pathways, where an individual may be more susceptible to the formation of active products but also be less susceptible to their subsequent detoxification. Despite this, genetic variation in drug metabolism may rarely be a simple susceptibility to DHRs, but instead metabolic rate may be a factor for the rate of onset of a DHR. Impaired renal clearance and co-morbidity are other important factors to consider. Therefore, individuals are still exposed to potentially immunogenic metabolites independent of metabolic rate and thus it is unclear how metabolic variation translates to a predisposition to hypersensitivity. This may be explained by danger signalling, as certain individuals would be exposed to higher and thus more toxic concentrations of certain compounds, and would therefore be subject to enhanced danger signalling and an enhanced likelihood of T-cell activation. 
One of the most extensively studied drugs with regards to the role of drug metabolism in DHRs is the sulfonamide antibiotic sulfamethoxazole (SMX). SMX is susceptible to N-acetylation by both N-acetyl transferase-1 (NAT1) and NAT2 enzymes. This process reduces the in vivo availability of SMX and the downstream metabolite nitroso SMX (SMX-NO), both of which can stimulate T-cells from hypersensitive patients. Thus, exposure to SMX-derived immunogenic antigens in a given individual is determined by the rates of metabolic activation and detoxification. As exposure of keratinocytes to SMX is associated with cell death, and the release of danger signals, ADDIN EN.CITE , a higher SMX concentration due to slower detoxification has the propensity to increase the likelihood of immune activation. Indeed, it has been found that patients with hypersensitivity more frequently express the NAT2 slow acetylator phenotype than do tolerant individuals. However, when Pirmohamed and colleagues addressed the role of acetylator genotype on predisposition to SMX hypersensitivity by investigating enzyme polymorphisms in HIV-positive patients with and without hypersensitivity, no significant associations were found. ADDIN EN.CITE 37 A number of studies have assessed the role of the microsomal NADH-dependent hydroxylamine reductase (NADHR)-mediated detoxification of SMX-hydroxylamine, an intermediate in the metabolism of SMX to the protein-reactive species SMX-NO. ADDIN EN.CITE , Differential expression or activity may affect the ability of an individual to reduce SMX.   Furthermore, promoting the formation of SMX-hydroxylamine and SMX-NO by manipulating redox cycling processes has been proposed to partly mediate SMX-NO-mediated cytotoxicity. Of interest, the anti-oxidants glutathione and ascorbate aid the formation of SMX-hydroxylamine by promoting the reduction of SMX-NO.40 However, similarly to NAT expression, genetic association analysis has ruled out a role for glutathione-S-transferase enzymes in the predisposition of an individual to these reactions. ADDIN EN.CITE 37 Interestingly, Wang et al demonstrated that HIV patients with rs761142 polymorphism in their glutamate cysteine ligase catalytic subunit (GCLC) had lower levels of GCLC mRNA expression and an increased incidence of SMX-induced hypersensitivity. However, in a more recent study by Reinhart et al investigating genetic risk factors associated with sulfonamide hypersensitivity in immunocompetent patients, the authors concluded that there was no genetic risk factor linked to the observed hypersensitivity reactions reported41. Therefore, while genetic association studies have not strongly supported  a role for genetic variations in metabolising enzymes for predisposition to SMX hypersensitivity, metabolic variants may influence the balance of a response towards a parent drug- or metabolite-specific reaction. Presumably, drug metabolism is also influenced by co-administration of other drugs, diet exercise etc. 
As metabolism seldom represents a one-step process, it is important to consider the implications of metabolism and detoxification pathways downstream of the parent compound, particularly in cases where metabolites are capable of activating T-cells. Indeed, the interplay of complex metabolism pathways is thought to account for the lack of association between isoniazid hepatotoxicity and acetylator phenotype.42 
 
Idiosyncratic DILI: clinical problems, genetics, lesson learnt and unanswered questions 
Idiosyncratic DILI presents with an array of clinical symptoms and can vary in severity from a mild increase in liver enzymes (alanine aminotransferase (ALT), bilirubin and alkaline phosphatase (ALP)) to acute liver failure and death. DILI is often difficult to distinguish from natural causes of liver injury such as viral hepatitis or autoimmune conditions. ADDIN EN.CITE 43 DILI often has a delayed onset (5 to >100 days) during continuous therapy and even may occur after cessation of therapy. Assessment is based on clinical and biochemical findings HYPERLINK \l "_ENREF_44" \o "Senior, 2009 #42"  ADDIN EN.CITE <EndNote><Cite><Author>Senior</Author><Year>2009</Year><RecNum>42</RecNum><DisplayText><style face="superscript">44</style></DisplayText><record><rec-number>42</rec-number><foreign-keys><key app="EN" db-id="59ttpfwpz50w5ler92o5f59hft5vx29z59xt" timestamp="1477057104">42</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Senior, J. R.</author></authors></contributors><auth-address>US FDA, Off Surveillance &amp; Epidemiol, Ctr Drug Evaluat &amp; Res, Silver Spring, MD USA</auth-address><titles><title>Monitoring for Hepatotoxicity: What Is the Predictive Value of Liver &quot;Function&quot; Tests?</title><secondary-title>Clinical Pharmacology &amp; Therapeutics</secondary-title><alt-title>Clin Pharmacol Ther</alt-title></titles><periodical><full-title>Clinical Pharmacology &amp; Therapeutics</full-title><abbr-1>Clin Pharmacol Ther</abbr-1></periodical><alt-periodical><full-title>Clinical Pharmacology &amp; Therapeutics</full-title><abbr-1>Clin Pharmacol Ther</abbr-1></alt-periodical><pages>331-334</pages><volume>85</volume><number>3</number><keywords><keyword>disease</keyword><keyword>surveillance</keyword><keyword>tuberculosis</keyword><keyword>troglitazone</keyword><keyword>injury</keyword><keyword>serum</keyword></keywords><dates><year>2009</year><pub-dates><date>Mar</date></pub-dates></dates><isbn>0009-9236</isbn><accession-num>ISI:000263606500023</accession-num><urls><related-urls><url>&lt;Go to ISI&gt;://000263606500023</url></related-urls></urls><electronic-resource-num>10.1038/clpt.2008.262</electronic-resource-num><language>English</language></record></Cite></EndNote>44 and accurate diagnosis with drug causality requires detailed case patient records reviewed by multiple expert hepatologists. Based on biochemical measures, three types of DILI can occur ADDIN EN.CITE 45 ‘hepatocellular’ caused by damage predominantly to hepatocytes, where serum ALT at the time of maximum elevation is greater than ALP, ‘cholestatic’ caused by disruption in biliary excretion of bilirubin, where serum bilirubin is elevated and ALP at the time of maximum elevation is greater than ALT and ‘mixed’, where ALT, ALP and bilirubin are elevated. A concomitant rise in ALT (>3x upper limit of normal range, ULN) and bilirubin (>2x ULN) is suggestive of severe liver injury where hepatocyte damage is coupled with disrupted biliary excretion, increased serum bilirubin and jaundice. These symptoms are collectively referred to as “Hy’s Law”. In cases analysed by Hy Zimmerman, Spanish and Swedish registries, ADDIN EN.CITE 46-48 concomitant ALT/bilirubin elevations are associated with a 10% mortality risk. Such cases of possible Hy’s Law require prompt and permanent discontinuation of the suspected drug to prevent further liver injury and possible mortality. DILI events typically resolve within 30 days following drug cessation, and in some situations adaptation during continuous treatment can occur, however the risk of DILI exacerbation following re-challenge means that drug reintroduction is contraindicated in cases where Hy’s Law criteria has been diagnosed. Since the lack of distinguishing diagnostic features and predictive or prognostic biomarkers for DILI makes it difficult to establish drug-induced DILI events, safety risk management in clinical trials must include regular monitoring of serum liver enzymes (ALT, ALP and bilirubin) levels, with defined thresholds for drug discontinuation and causality determination of potential DILI cases by hepatologist expert adjudication. Since DILI events can occur rapidly, at any time during drug treatment and may occur between monitoring visits, frequent serum liver enzyme monitoring in clinical trials is recommended for early safety evaluation and management, however this is not always achieved. Where HLA alleles are validated for DILI risk, a possible safety management approach may be to schedule risk allele carriers for more frequent liver chemistry monitoring than non-risk allele carriers. The delayed onset of liver injury (several days to several months) and development of more rapid and more severe symptoms following inadvertent re-challenge are indicative of an adaptive immune mechanism. Moreover, analysis of liver from patients with flucloxacillin- and sulfasalazine-induced liver injury showed an increase in T-cells secreting the cytolytic molecule granzyme B, ADDIN EN.CITE , which suggests that T-cells might play a direct role in the disease pathogenesis. In contrast to the skin reactions, the role of drug-specific T-cells in reactions targeting liver has not been extensively investigated. An early study detected T-cells in blood of certain DILI patients could be activated in vitro in the presence of the suspect drug(s),51 however, the phenotype and function of these cells were not investigated and additional studies have not been forthcoming. For this reason, the team in the CDSS has recently focussed on three drugs: flucloxacillin, co-amoxiclav and isoniazid, and in each case drug-responsive T-cells have been detected in patients with liver injury. Drug-specific T-cells were cloned and characterized in terms of cellular phenotype, HLA-restriction and mechanisms of cytotoxicity. ADDIN EN.CITE , 
The association between MHC class I alleles and a number of drug reactions has been well established. ADDIN EN.CITE 53 Notably, HLA-B*57:01 is associated with abacavir hypersensitivity syndrome ADDIN EN.CITE 54 and with pazopanib- and flucloxacillin-induced liver injury. ADDIN EN.CITE , However, it is now clear that abacavir and flucloxacillin bind to HLA*B57:01, and initiate immune responses in different ways. The molecular interaction between pazopanib and HLA-B*57:01 has not been characterised. The mechanism of immune response proposed for the pathogenesis of abacavir hypersensitivity involves a non-covalent interaction between the drug molecule and the F-pocket of the HLA-B*57:01 binding groove. The outcome is an alteration in the repertoire of self-peptides presented to T-cells, and subsequent activation of the immune system. ADDIN EN.CITE , Interestingly, the molecular mechanism of T-cell activation by flucloxacillin is dependent on a number of variables. Flucloxacillin is a β-lactam antibiotic that generates protein adducts spontaneously through nucleophilic attack by amino acids and ring opening. ADDIN EN.CITE 58 Wuillemin et al demonstrated that while T-cells generated from HLA-B*57:01-negative healthy donors were activated via a processing-dependent pathway by flucloxacillin-modified peptide (hapten hypothesis), T-cells generated from HLA-B*57:01-positive healthy donors responded to the drug antigen via a processing-independent, non-covalent interaction of flucloxacillin with HLA-B*57:01 allele (pharmacological interaction with immune receptors). ADDIN EN.CITE 59 The pathways of flucloxacillin-induced T-cell activation were also studied by Yaseen et al. ADDIN EN.CITE 60 Specifically, they compared the mechanism of T-cell activation using T-cells generated from both DILI patients and healthy volunteers. They demonstrated that in contrast to T-cell clones from healthy donors; those from patients with DILI were activated with flucloxacillin via the hapten mechanism. Moreover, the response to flucloxacillin-modified peptides was highly HLA allele-restricted. These data suggest that the pathway of T-cell activation by flucloxacillin may be dependent on multiple factors including, the expression of the HLA-B*57:01 risk allele and disease. 
In contrast to the HLA class I-restricted reactions, as yet no findings have linked the expression  of specific HLA class II risk alleles to the activation of drug-specific T-cells in drug involved in drug hypersensitivity. Thus, two speakers from the pharmaceutical industry were invited to discuss the potential role of MHC class II alleles in DILI.
Michael Kammüller (Novartis) gave insight into the clinical problems and genetics of lumiracoxib-induced liver injury. Lumiracoxib is a selective COX-2 inhibitor indicated for osteoarthritis and acute pain. It has favourable PK properties, attaining a high concentration in the synovial fluid relative to the plasma. Furthermore, this drug had a better safety profile on the gastrointestinal tract when compared with the non-selective COX-1/2 inhibitors. ADDIN EN.CITE 61 However, signs of reversible transaminase elevations were observed during the development program, ADDIN EN.CITE 61 thus prompting a product labelling requiring monthly hepatic monitoring in chronic administration. In a large randomised controlled trial, the proportion of patients with transaminase concentrations >3x ULN differed significantly between lumiracoxib (2.6%) and non-steroidal anti-inflammatory drugs (0.6%), but changes were reversible on drug discontinuation. ADDIN EN.CITE 61 Cases of liver injury, liver failure and death associated with lumiracoxib were observed during post-marketing surveillance. ADDIN EN.CITE , Although the exact mechanism of lumiracoxib-induced liver injury is unclear, the genetics of susceptible individual appears to be an important risk factor, indicating an immune-mediated pathogenesis. An exploratory genome-wide association study of 41 cases (>5 x ULN ALT/AST) and 176 matched controls identified a significant association with the MHC class II region.34 HLA fine mapping identified a highly significant association with the haplotype (HLA-DRB1*15:01-HLA-DQB1*06:02-HLA-DRB5*01:01-HLA-DQA1*01:02, P = 6.8 x 10-25; allelic odds ratio = 5.0, 95% CI 3.6-7.0). Among patients with liver enzyme elevations, carriers of the HLA-DQA1*01:02 allele had more severe hepatotoxicity than did non-carriers. Restriction by human MHC class II alleles may explain the lack of predictability of preclinical toxicology studies for human hepatotoxicity. Moreover, the convergence of exogenous and endogenous risk factors, which likely determine frequency and severity of rare events such as DILI in humans, is not present in currently used preclinical animal models. Initial studies using naïve T-cells from healthy volunteers with this haplotype have failed to detect lumiracoxib-specific T-cells. However, it is important to note that not all individuals that express the above-mentioned haplotype develop lumiracoxib-induced liver injury. Therefore, characterising the importance of this allele in the mechanism of lumiracoxib-induced liver-injury remains an unmet need. In view of the delayed onset of lumiracoxib-induced liver-injury (weeks to months after initiation of drug treatment), a more detailed characterisation of the various stages (initiation, progression and repair or adaptation) and events of DILI will be essential. This information may help in identifying risk factors, biomarkers and the molecular mechanisms involved in disease pathogenesis over and above the HLA class II associations. Both the chemistry of drug-antigen and patients’ immunogenic susceptibility factors need to be considered during clinical and mechanistic studies. The lack of liver biopsies, patients’ peripheral mononuclear cells (PBMCs), urine and DNA are obvious limitations to mechanistic studies. The ultimate challenge for drug safety sciences remains to identify drugs with the potential to cause HLA-associated DILI at the early stages of drug discovery without the risk of discarding potentially valuable new drugs.
Colin Spraggs (GlaxoSmithKline) discussed the genetics of lapatinib-induced liver injury. Lapatinib (Tykerb/TyverbTM Novartis, formerly GlaxoSmithKline), is an inhibitor of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), receptor tyrosine kinases, which are signalling pathways for tumor growth. Lapatinib is approved for use within the US, EU and a number of other countries for the treatment of HER2-positive metastatic breast cancer, in combination with chemotherapy, such as trastuzumab, ADDIN EN.CITE 64 capecitabine or letrozole. ADDIN EN.CITE , The potential for liver toxicity was not identified in pre-clinical animal toxicology studies of lapatinib. However, during clinical trial evaluation, a small proportion of lapatinib-treated patients experienced isolated elevated serum alanine transaminase (ALT>5x upper limit of normal (ULN)) (3%) and/or concomitant elevated ALT (>3x ULN) with elevated serum bilirubin (>2x ULN), consistent with possible Hy’s Law cases (0.6%).62 These findings resulted in prominent ‘Black Box’ safety warnings for hepatotoxicity in Tykerb/Tyverb product labelling. Liver injury during lapatinib treatment exhibits a variable, but typically late onset elevation in ALT, which resolves upon lapatinib discontinuation. Symptoms may resume rapidly during re-challenge; a pattern consistent with a delayed immunological hypersensitivity reaction. Lapatinib is metabolised primarily by CYP3A4 and CYP3A5, with minor contribution from CYP2C8 and CYP2C19. ADDIN EN.CITE 67 The formation of protein-reactive quinone imine metabolites, possibly generating neoantigens that can activate the immune system has been demonstrated using a number of in vitro systems. ADDIN EN.CITE ,HYPERLINK \l "_ENREF_65" \o "Teng, 2010 #38" Genome-wide screening of prospectively collected clinical trial samples performed to assess the significance of pharmacogenetic factors in lapatinib-induced liver injury implicated HLA-DQA1*02:01 and HLA-DRB1*07:01 (which are co-inherited) as risk alleles. ADDIN EN.CITE 70-73 Patients that expressed the HLA-risk alleles had higher ALT elevations and Hy’s Law risk. The association of MHC class II risk alleles suggests that the adaptive immune system may play a role the pathogenesis of lapatinib-induced liver injury in susceptible patients. To date however, no HLA binding studies have been carried out to investigate the interaction of either lapatinib or its reactive metabolites with these risk alleles. Moreover, lapatinib (metabolite)-specific T-cells have not been isolated from DILI patients or healthy volunteers post priming. Thus, similar to lumiracoxib, a knowledge gap exists in our understanding of the molecular basis of lapatinib-induced liver injury, most especially how the presence of HLA-DQA1*02:01 and HLA-DRB1*07:01 regulate immune responses resulting in DILI. 

Immunological studies on patients with natural liver injury
Gideon Hirshfield (University of Birmingham, UK) presented on the role of the immune system in naturally occurring hepatic disease. He and his colleagues are interested in liver diseases of varying aetiology, some of which are associated with HLA risk alleles, mostly HLA class II alleles. Their major research interest is primary biliary cirrhosis (PBC), which is associated with a number of HLA class II alleles in European and Japanese populations. However, the exact role of the implicated HLA alleles in the pathophysiology of PBC remains to be defined. Following a liver transplant, a biopsy is taken to isolate various cellular subsets such as liver infiltrating lymphocytes, hepatocytes and sinusoidal endothelial cells for further in-depth analysis. He described four cellular compartments implicated in DILI, namely: liver, bile duct, gut and immune compartments. Interestingly, although genome-wide association studies have strongly implicated certain HLA alleles, other genes such as IL-12, IRF5, CXCR5 and SOCS1 have been identified as important in the immunoregulation of PBC. ADDIN EN.CITE 74-76 Furthermore, analysis of the cytokine microenvironment of tissue infiltrates has implicated Th1 cells in early disease while Th17 cells predominate in the later stages of PBC. ADDIN EN.CITE 77 Such qualitative data provides important information for the clinical management of patients, most of who are diagnosed late in the disease process. Access to and analysis of clinical samples (liver tissues and whole blood) to investigate the molecular pathomechanisms of DILI is critical. There is a need for the rigorous phenotyping of T-cells from liver biopsies to assess the role of different populations of infiltrating T-cells in the different forms of drug-induced liver disease.

Moving Forward:
Critical questions: (1) Why are specific organs (skin, liver, heart, brain etc.) targeted by the immune system? (2) What are the molecular mechanisms underlying HLA risk alleles? (3) Why do only some patients with risk alleles develop DHRs? (4) What are the critical events that cause immune activation in the tolerogenic environment of the liver?

LESSONS FROM PATIENTS WITH CUTANEOUS HYPERSENSITIVITY REACTIONS
Skin reactions are traditionally listed as the most frequently observed reactions to drugs. Drug-induced skin injury affects about 2-3% of hospitalised patients. ADDIN EN.CITE , Morphologically, these reactions can be subdivided into maculopapular rash, bullous reactions (SJS/TEN), pustular reactions (AGEP) and hypersensitivity syndromes. Given the varying clinical presentations, it is unlikely that a single mechanism of T-cell recognition/activation is responsible for all the types of drug-induced cutaneous eruption. Drug-specific cytotoxic CD8+T-cells have been implicated in the death of keratinocytes, resulting in skin detachment observed in drug-induced SJS and TEN. ADDIN EN.CITE , A number of studies have implicated CD4+ T-cells in the pathogenesis of milder drug reactions. ADDIN EN.CITE ,, However, it is still not clear whether these CD4+ cells are activated to secrete the same effector molecules as cytotoxic CD8+ T-cells in patients. The different phenotypes of drug-induced cutaneous adverse reactions are summarised below.

Maculopapular exanthemas (MPE) and Fixed drug Eruptions (FDE)
Maculopapular simply refers to the generalised morphology of the rash which is observed as macules or papules which are flat or raised skin lesions of up to 1cm in diameter respectively. This lends itself to the description of these reactions as exanthematous in reference to these eruptions. Other commonly used descriptions include the term morbilliform eruption alluding to similarities to the eruptions seen with measles infection. Indeed, MPE may be caused by certain diseases such as lymphoma and by viruses like cytomegalovirus and herpes, however it is most often induced by drugs.84 There is still some confusion surrounding the exact mechanism of drug-induced MPE but it may be that there are two; one being a Th2 response with subsequent eosinophil recruitment and the involvement of interleukin (IL)-4 and IL-5, the other a joint CD4/CD8 cytotoxic response involving various cell death pathways including Fas-FasL, perforin, and granzyme B.85 Other mild and generalised reactions may not affect the entire body, but just one area. For example, fixed drug eruptions (FDE) are characterised by recurring skin lesions, on the same area of the skin, in response to repeated exposure to an antigenic drug. FDE is often associated with accompanying nausea, vomiting, and fever, and lesions in the skin of patients with these reactions have infiltrating lymphocytes as well as neutrophils and eosinophils.86 Upon recognition of FDE, the drug is usually withdrawn and topical steroids administered.87 There are, however, a number of better defined hypersensitivity reactions, which are detailed below.

Acute Generalised Exanthematous Pustulosis (AGEP)
AGEP is a rare cutaneous reaction which is estimated to affect a maximum of just 5 cases per million per year,88 and with 5% mortality. It is classified as more serious than MPE which is essentially non-lethal.89 This reaction is often observed less than 48 hours after initial drug administration but spontaneously resolves by around 2 weeks. Due to this rapid resolution, patients may be treated with corticosteroids but the vast majority only require supportive care.90 Morphologically, AGEP defines a rash formed of numerous pustules atop an inflamed, reddened section of skin and is strongly linked to simultaneous development of fever, as are to a lesser extent symptom such as blisters and facial oedema. In approximately one fifth of cases there is involvement of mucus membranes, particularly that of the mouth.90 A wide variety of drugs have been associated with AGEP including many anti-infective agents such as the sulfonamides containing medication co-trimoxazole, and much more common over-the-counter drugs such as acetaminophen., While both CD4 and CD8 T-cells are implicated in these reactions, more defining is the fact that these responsive T-cells are able to recruit and induce neutrophils through the production of IL-8. In fact, it is this large influx of neutrophils that forms the sterile pustular eruptions associated with AGEP.93

Drug reaction with eosinophilia and systemic symptoms (DRESS)
DRESS, also referred to as drug hypersensitivity syndrome (DHS), is considered a severe cutaneous adverse reaction due to a mortality rate of 10%, double that of AGEP.89 The key distinguishing features of this reaction are, as its name implies, eosinophil involvement and immersion of this reaction within a number of systems other than the skin, which include the liver and hematologic system.94 DRESS has a reported incidence of 1 in 10,000 exposures and a delayed onset of 2-6 weeks post drug exposure. Associated symptoms are fever, eosinophilia, lymphadenopathy, severe skin eruption, and the inability of drug withdrawal to reduce symptoms. ADDIN EN.CITE , Other features are often present such as facial oedema, involvement of the liver, kidneys, lungs, and/or heart, with liver failure being the major cause of death for DRESS patients. Both CD4+ and CD8+ T-cells are thought to be involved which produce IL-5 prior to eosinophil recruitment.97 Recently, most interest in DRESS surrounds the potential role of viral reactivation in the induction of this reaction. Reactivation of cytomegalovirus, Epstein-Barr virus, and HHV6/7 has been linked with DRESS, which is thought to arise due to a hypogammaglobulinaemic environment induced by the culprit drug. For this scenario it is the viral reactivation that is then responsible for the development of DRESS which accounts for the lengthy time to onset due to the time required for viral expansion. ADDIN EN.CITE ,.However, it is also possible that it is the drug-specific activation of T-cells that reactivates the virus. Identifying which comes first, drug-specific T-cell activation or viral activation, is hindered by the fact that viral deoxyribonucleic acid (DNA) and virus-specific IgE, which are routinely used to assess viral activity, are only able to be measured many weeks after onset of a reaction.99 Oral corticosteroids and drug withdrawal are used to treat DRESS, as is the immunosuppressive agent cyclosporine. At least 50 drugs are known to cause DRESS.95
A key question that remains unanswered is: what is the mechanism of viral re-activation since this can be triggered by different drugs in DRESS patients? Philippe Musette (Rouen University Hospital, France) discussed recent findings of his group showing reactivation of multiple viruses (HHV6, CMV and EBV) in 80% of DRESS patients (n = 40) recruited in France. The reason why viral reactivation is not observed in the remaining 20% of patients is unclear. Musette also described the expansion of EBV-specific CD8+ T-cells in DRESS patients. ADDIN EN.CITE 100 T-cells reactive against viruses migrate to the skin and the liver, and cutaneous eruptions ensue upon re-exposure to “culprit drug”. An obvious knowledge gap is whether these viral-specific T-cells are capable of cytotoxicity in the same manner as other drug-specific T-cells that can be isolated from the same patients. The involvement of cytokines in DRESS was also discussed by Musette. IL-2, IL-10 and TNF-α have all been shown to be upregulated in patients with DRESS. These cytokines can be modulated and viral reactivation blocked; thus, providing a potential treatment option in the management of DRESS patients. Since cytokines and a pro-inflammatory microenvironment are important factors in the pathogenesis of DRESS, Musette emphasized the need to access PBMCs from patients and tolerant controls during clinical trials to allow prospective mechanistic studies. One other factor yet to be fully explored in the development of cutaneous reactions such as DRESS is the role of regulatory T-cells (Tregs). These CD25+ CD4+ T-cells, which account for 5-10% of all circulating CD4+ T-cells, function to primarily suppress effector T-cell responses.101 Musette concluded by hypothesizing that secretion of IL-10 and TNF-α, as a result of both drug and viral recognition, are important determinants of the severity of clinical symptoms in the pathogenesis of DRESS. Delegates agreed that further experiments are required to determine the relative importance of the drug and viruses in activating an inappropriate immune response in DRESS patients. Also, given the diversity of implicated viruses, new technologies need to be applied to further explore the contribution of viruses to the disease pathogenesis.  

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)
The most serious cutaneous reactions, due to their high mortality rates, are SJS and TEN. These two reactions are in fact thought to be variants of the same reaction, differing in terms of severity, and affecting between 10-30% of the epidermis. SJS and TEN are categorised by the extent of skin detachment, with TEN being the more debilitating. SJS and TEN are caused by a myriad of drugs such as NSAIDs, antibiotics, anticonvulsants, sulfonamides, and allopurinol. SJS/TEN has a reaction onset time of between 1-3 weeks. Both of these reactions are associated with characteristic blistered lesions that are described as painful with a burning sensation. ADDIN EN.CITE ,  In fact, the treatment of SJS/TEN has many similarities to that of a severe burn, and indeed the specialist care of a burn unit is often required for SJS/TEN patients. Although considered a life threatening cutaneous reaction, if the drug is withdrawn and the reaction dampened, the skin of patients with SJS/TEN recovers far more quickly than that of burn patients, as the reaction is limited to the epidermis in SJS/TEN.103
SJS involves a skin reaction with 10% body coverage and 1-5% mortality, while TEN classification requires 30% body coverage and is associated with 30-50% mortality.104 The initial damage during SJS/TEN is actually keratinocyte apoptosis, with epidermal necrolysis occurring later in the reaction causing the characteristic skin detachment as the epidermis and dermis separate.102 SJS occurs more frequently than TEN with incidences of 1-2 cases and 0.4-1.2 cases per million person per year, respectively.105 In both SJS and TEN, lesions have been found to contain natural killer T-cells (NKT) and cytotoxic T-cells as the effector cells responsible for the associated keratinocyte death.106 The skin homing receptor CLA appears to be particularly important in recruitment of these T-cells to the skin as patient T-cells obtained from blister fluid have four-fold higher CLA expression than PBMCs. The T-cell response, which involves both CD4 and CD8 T-cells, leads to the secretion of IFN-γ, which through inducing secretion of tumour necrosis factor (TNF)-α, as well as expression of human leukocyte antigen (HLA)-DR and Fas on keratinocytes, leads to the death of epidermal cells.107 Indeed, blister fluid, as well as the epidermis, have been reported to contain cytokines such as IFN-γ, TNF-α, and FasL.102 The role of FasL is of particular interest as groups have been able to show effective Fas-FasL inhibition of skin detachment using both synthetic blocking antibodies as well as natural anti-Fas antibodies found in intravenous immunoglobulins (IVIG). Initial reports have highlighted IVIG therapy as highly effective, with reduced skin detachment in all ten patients tested.102 However while FasL represents a possible therapeutic approach, the major cytotoxic effector during SJS-TEN seems to be granulysin which therefore has great therapeutic and diagnostic potential. Specifically, granulysin concentrations in the blister fluid of patients have been shown to be 2 to 4-fold higher than concentrations of other cytolytic mediators including FasL, granzyme B and perforin. This high expression translates to a significant functional effect, as mice exposed to granulysin from the blister fluid of patients developed SJS-TEN-like features, without the addition of any other factors.108 

Immunological studies on patients’ tissue
To understand that aetiology of cutaneous hypersensitivity reactions it is important to define the role of individual T-cell subsets. Traditionally, it was considered that two distinct CD4 T-cell subsets could be generated from the naïve CD4 (Th0) population which were defined by distinct cytokine secretion patterns. Th1 cells are considered pro-inflammatory and defined by the ability to secrete IFN-γ and IL-2, while Th2 cells are anti-inflammatory and secrete cytokines such as IL-4 and IL-5. Th1 cell development is driven by the transcription factors T-bet and STAT4, subsequent to which they activate NK cells and macrophages, and expand cytotoxic CD8+ T-cells to protect against intracellular viruses and bacteria largely through the secretion of IFN-type cytokines. Th2 cells on the other hand are induced by the expression of GATA3 and STAT5 and act to control pathogenic infections such as from helminths, but also bacterial and viral infections, by promoting eosinophil- and IgE-mediated responses., However, in recent years, a number of new T-cell subsets have been identified. Lesser known Th subsets include T follicular helper cells (Tfh), which aid antibody class switching and the secretion of antibodies with high affinity, ADDIN EN.CITE 111-114 and Th9 cells, so called because of their profound IL-9 secretion, and reported to be involved in autoimmune and allergic disease development. However, two distinct subsets termed Th17 and Th22 cells have received the greatest attention with regards to hypersensitivity reactions as both appear to have important consequences in the skin, particularly Th22 cells which are enhanced in patients with psoriasis, atopic eczema, and  allergic contact dermatitis.115 Both Th17 and Th22 cells have dual capabilities; they can induce an anti-inflammatory innate immune response in keratinocytes to protect skin, but they also have a pro-inflammatory function. Specifically, Th22 cells promote the secretion of chemokines and cytokines from keratinocytes in inflamed skin thus enhancing the immune response. However, they also maintain the integrity of the skin by inducing the proliferation of keratinocytes.  In contrast, the pro-inflammatory effects of Th17 cells are more pronounced as they ultimately lead to keratinocyte death through apoptosis due to upregulation of specific adhesion molecules. While both Th17 and Th22 cells secrete IL-22, the more prominent pro-inflammatory effects mediated by Th17 cells are due to the combined effects of IL-17 and IFN-γ.116 Of immense importance are new mechanistic studies using cells from patients with cutaneous hypersensitivity to define the involvement (or not) of these new T-cell populations in the disease pathogenesis. Data derived from these studies will allow reclassification of hypersensitivity reactions by updating the system proposed by Pichler in 2003.4  




Innate immune response to chemicals and induction of drug hypersensitivity reactions 
In 1994, Matzinger and colleagues proposed a radical new concept for T-cell activation. Specifically she stated that a T-cell is tipped towards a responsive state if an antigen is presented to it in a “stressful” environment. This was termed the danger hypothesis and was rapidly applied to drug hypersensitivity. ADDIN EN.CITE , The idea is that if a drug is directly toxic to cells it will induce cell damage and potentially cell death. Antigen presenting cells consequently upregulate co-stimulatory molecule expression on their cell surface in response to stimuli from these dead cells which renders these cells ready for T-cell stimulation. HYPERLINK \l "_ENREF_119" \o "Li, 2010 #115"  ADDIN EN.CITE <EndNote><Cite><Author>Li</Author><Year>2010</Year><RecNum>115</RecNum><DisplayText><style face="superscript">119</style></DisplayText><record><rec-number>115</rec-number><foreign-keys><key app="EN" db-id="59ttpfwpz50w5ler92o5f59hft5vx29z59xt" timestamp="1477057134">115</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Li, Jinze</author><author>Uetrecht, JackP</author></authors><secondary-authors><author>Uetrecht, Jack</author></secondary-authors></contributors><titles><title>The Danger Hypothesis Applied to Idiosyncratic Drug Reactions</title><secondary-title>Adverse Drug Reactions</secondary-title><tertiary-title>Handbook of Experimental Pharmacology</tertiary-title></titles><pages>493-509</pages><volume>196</volume><section>18</section><keywords><keyword>HMGB1</keyword><keyword>Heat shock proteins</keyword><keyword>S100 proteins</keyword><keyword>Reactive metabolites</keyword><keyword>Immune-mediated</keyword></keywords><dates><year>2010</year><pub-dates><date>2010/01/01</date></pub-dates></dates><publisher>Springer Berlin Heidelberg</publisher><isbn>978-3-642-00662-3</isbn><urls><related-urls><url>http://dx.doi.org/10.1007/978-3-642-00663-0_18</url></related-urls></urls><electronic-resource-num>10.1007/978-3-642-00663-0_18</electronic-resource-num><language>English</language></record></Cite></EndNote>119 Endogenous danger signals from dead cells are effectively the spilled contents of the cells and are known as DAMPs (damage associated molecular patterns), and include HMGB1 (high mobility group box-1 protein), S100 proteins, and heat shock proteins. HYPERLINK \l "_ENREF_119" \o "Li, 2010 #115"  ADDIN EN.CITE <EndNote><Cite><Author>Li</Author><Year>2010</Year><RecNum>115</RecNum><DisplayText><style face="superscript">119</style></DisplayText><record><rec-number>115</rec-number><foreign-keys><key app="EN" db-id="59ttpfwpz50w5ler92o5f59hft5vx29z59xt" timestamp="1477057134">115</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Li, Jinze</author><author>Uetrecht, JackP</author></authors><secondary-authors><author>Uetrecht, Jack</author></secondary-authors></contributors><titles><title>The Danger Hypothesis Applied to Idiosyncratic Drug Reactions</title><secondary-title>Adverse Drug Reactions</secondary-title><tertiary-title>Handbook of Experimental Pharmacology</tertiary-title></titles><pages>493-509</pages><volume>196</volume><section>18</section><keywords><keyword>HMGB1</keyword><keyword>Heat shock proteins</keyword><keyword>S100 proteins</keyword><keyword>Reactive metabolites</keyword><keyword>Immune-mediated</keyword></keywords><dates><year>2010</year><pub-dates><date>2010/01/01</date></pub-dates></dates><publisher>Springer Berlin Heidelberg</publisher><isbn>978-3-642-00662-3</isbn><urls><related-urls><url>http://dx.doi.org/10.1007/978-3-642-00663-0_18</url></related-urls></urls><electronic-resource-num>10.1007/978-3-642-00663-0_18</electronic-resource-num><language>English</language></record></Cite></EndNote>119 No signalling occurs in the case of natural cell turnover where dying cells are effectively scavenged long before they could disintegrate, but signals are released in response to drug-induced necrotic cell death. Indeed, expression profiles of genes associated with oxidative stress changed shortly after administration of tielinic acid which is linked with hepatotoxicity, HYPERLINK \l "_ENREF_120" \o "Pacitto, 2007 #116"  ADDIN EN.CITE <EndNote><Cite><Author>Pacitto</Author><Year>2007</Year><RecNum>116</RecNum><DisplayText><style face="superscript">120</style></DisplayText><record><rec-number>116</rec-number><foreign-keys><key app="EN" db-id="59ttpfwpz50w5ler92o5f59hft5vx29z59xt" timestamp="1477057134">116</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Pacitto, Stephanie R.</author><author>Uetrecht, Jack P.</author><author>Boutros, Paul C.</author><author>Popovic, Marija</author></authors></contributors><titles><title>Changes In Gene Expression Induced by Tienilic Acid and Sulfamethoxazole: Testing the Danger Hypothesis</title><secondary-title>Journal of Immunotoxicology</secondary-title></titles><periodical><full-title>Journal of Immunotoxicology</full-title></periodical><pages>253-266</pages><volume>4</volume><number>4</number><dates><year>2007</year></dates><urls><related-urls><url>http://informahealthcare.com/doi/abs/10.1080/15476910701680020</url></related-urls></urls><electronic-resource-num>doi:10.1080/15476910701680020</electronic-resource-num></record></Cite></EndNote>120 and dendritic cell expression of CD40 is enhanced by SMX-NO. HYPERLINK \l "_ENREF_121" \o "Sanderson, 2007 #117"  ADDIN EN.CITE <EndNote><Cite><Author>Sanderson</Author><Year>2007</Year><RecNum>117</RecNum><DisplayText><style face="superscript">121</style></DisplayText><record><rec-number>117</rec-number><foreign-keys><key app="EN" db-id="59ttpfwpz50w5ler92o5f59hft5vx29z59xt" timestamp="1477057135">117</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Sanderson, Joseph P.</author><author>Naisbitt, Dean J.</author><author>Farrell, John</author><author>Ashby, Charlotte A.</author><author>Tucker, M. Jane</author><author>Rieder, Michael J.</author><author>Pirmohamed, Munir</author><author>Clarke, Stephen E.</author><author>Park, B. Kevin</author></authors></contributors><titles><title>Sulfamethoxazole and Its Metabolite Nitroso Sulfamethoxazole Stimulate Dendritic Cell Costimulatory Signaling</title><secondary-title>The Journal of Immunology</secondary-title></titles><periodical><full-title>The Journal of Immunology</full-title></periodical><pages>5533-5542</pages><volume>178</volume><number>9</number><dates><year>2007</year><pub-dates><date>May 1, 2007</date></pub-dates></dates><urls><related-urls><url>http://www.jimmunol.org/content/178/9/5533.abstract</url></related-urls></urls><electronic-resource-num>10.4049/jimmunol.178.9.5533</electronic-resource-num></record></Cite></EndNote>121 One particular DAMP which has received considerable attention is uric acid, a product of homeostatic nucleic acid turnover. When an individual develops hyperuricemia, monosodium urate (MSU) crystals are deposited, particularly in the joints. These crystals are able to stimulate the NLRP3 inflammasome to produce the effector cytokine, IL-1β. The associated inflammatory response is known as gout. It appears that uric acid is a strong and therefore important danger signal as its depletion alone in mice can significantly dampen the immune response to induce cell death. In contrast, a similar effect was not detected in response to other inflammatory inducers such as sterile irritants or microbes indicating that certain DAMPs are selective for specific inflammatory responses. ADDIN EN.CITE , Dead cells are known to release intracellular stores of uric acid, which promotes an acute inflammatory response. ADDIN EN.CITE ,, Since most reactive drug metabolites induce direct toxicity, it is possible that uric acid released from tissue cells, such as keratinocytes, promotes inflammation that directs the  nature of the adaptive response initiated against the drug antigen.   In comparison, other DAMPs are involved in a wide array of inflammatory responses, such as HMGB1 which is found in response to both infectious and non-infectious stimuli. Interestingly, although danger signals are associated with inflammation, HMGB1 has also been observed to aid tissue repair and to restore damaged tissue. HYPERLINK \l "_ENREF_126" \o "Klune, 2008 #120"  ADDIN EN.CITE <EndNote><Cite><Author>Klune</Author><Year>2008</Year><RecNum>120</RecNum><DisplayText><style face="superscript">126</style></DisplayText><record><rec-number>120</rec-number><foreign-keys><key app="EN" db-id="59ttpfwpz50w5ler92o5f59hft5vx29z59xt" timestamp="1477057135">120</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Klune, John R.</author><author>Dhupar, Rajeev</author><author>Cardinal, Jon</author><author>Billiar, Timothy R.</author><author>Tsung, Allan</author></authors></contributors><titles><title>HMGB1: Endogenous Danger Signaling</title><secondary-title>Molecular Medicine</secondary-title></titles><periodical><full-title>Molecular Medicine</full-title></periodical><pages>476-484</pages><volume>14</volume><number>7-8</number><dates><year>2008</year><pub-dates><date>Jul-Aug&#xD;04/11&#xD;03/17/received&#xD;04/10/accepted</date></pub-dates></dates><publisher>ScholarOne</publisher><isbn>1076-1551&#xD;1528-3658</isbn><accession-num>PMC2323334</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2323334/</url></related-urls></urls><electronic-resource-num>10.2119/2008-00034.Klune</electronic-resource-num><remote-database-name>PMC</remote-database-name></record></Cite></EndNote>126 Other danger signals arising from exogenous sources such as bacterial LPS or viral RNA and are known as PAMPs (pathogen associated molecular patterns). HYPERLINK \l "_ENREF_127" \o "Kumar, 2011 #121"  ADDIN EN.CITE <EndNote><Cite><Author>Kumar</Author><Year>2011</Year><RecNum>121</RecNum><DisplayText><style face="superscript">127</style></DisplayText><record><rec-number>121</rec-number><foreign-keys><key app="EN" db-id="59ttpfwpz50w5ler92o5f59hft5vx29z59xt" timestamp="1477057135">121</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kumar, Himanshu</author><author>Kawai, Taro</author><author>Akira, Shizuo</author></authors></contributors><titles><title>Pathogen Recognition by the Innate Immune System</title><secondary-title>International Reviews of Immunology</secondary-title></titles><periodical><full-title>International Reviews of Immunology</full-title></periodical><pages>16-34</pages><volume>30</volume><number>1</number><dates><year>2011</year></dates><accession-num>21235323</accession-num><urls><related-urls><url>http://informahealthcare.com/doi/abs/10.3109/08830185.2010.529976</url></related-urls></urls><electronic-resource-num>doi:10.3109/08830185.2010.529976</electronic-resource-num></record></Cite></EndNote>127 Infection is a well-known danger signal for developing DHRs as exemplified by enhanced susceptibility to isoniazid hepatotoxicity with concomitant chronic hepatitis and HIV. HYPERLINK \l "_ENREF_128" \o "Kaplowitz, 2005 #17"  ADDIN EN.CITE <EndNote><Cite><Author>Kaplowitz</Author><Year>2005</Year><RecNum>17</RecNum><DisplayText><style face="superscript">128</style></DisplayText><record><rec-number>17</rec-number><foreign-keys><key app="EN" db-id="zpesratas5tap0ezdw85ts5ztvfe90tep5pt" timestamp="1406903130">17</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kaplowitz, Neil</author></authors></contributors><titles><title>Idiosyncratic drug hepatotoxicity</title><secondary-title>Nat Rev Drug Discov</secondary-title></titles><periodical><full-title>Nat Rev Drug Discov</full-title></periodical><pages>489-499</pages><volume>4</volume><number>6</number><dates><year>2005</year><pub-dates><date>06//print</date></pub-dates></dates><isbn>1474-1776</isbn><work-type>10.1038/nrd1750</work-type><urls><related-urls><url>http://dx.doi.org/10.1038/nrd1750</url></related-urls></urls></record></Cite></EndNote>128 These viral danger signals instigate myeloid dendritic cell production of CD1d mRNA leading to activation of NKT cells. 
Contact allergy is an inflammatory disease of the skin triggered by protein-reactive, low molecular weight organic chemicals and metals. The incidence in the general population has been estimated as 15-20%.129 The main effector cells in contact allergy are CD8+ T-cells with Th1 and Th17 cells and CD4+CD25+ICOS+ Treg and iNKT cells responsible for supporting the cytotoxic response and immune regulation, respectively. Contact allergens induce cellular stress and damage resulting in the production and release of danger signals critical for immune activation and skin inflammation. The activation of the innate immune cells upon compound exposure almost always precedes an inflammatory response and this process can be mimicked in vitro by culturing chemicals with dendritic cells at sub-toxic and toxic concentrations. Stefan Martin (University of Freiburg, Germany) and his colleagues have used the mouse model, MEST (Mouse Ear Swelling Test) to investigate the potential of chemicals to elicit contact hypersensitivity and the role of specific immune cells (effector T-cells, mast cells, Tregs, dendritic cells) in the reaction. The test consists of sensitization and elicitation phases. Sensitization can either be performed via skin painting or through intracutaneous injection of dendritic cells that have been modified in vitro. Measurement of ear swelling upon re-challenge or elicitation with the allergen of interest provides an assessment of the strength of the induced response. Using this model, the role of the different cellular components implicated in allergic contact dermatitis has been characterised. For example, neutrophil depletion before sensitization or before re-challenge has been shown to abrogate contact hypersensitivity. ADDIN EN.CITE 130
The innate immune response to pathogens is mediated by one or more Toll-like receptors (TLRs), reactive oxygen species (ROS) and NOD-like receptors. Interestingly, nickel and cobalt can bind directly to human but not mouse TLR4, and induce receptor dimerization with subsequent innate immune activation. ADDIN EN.CITE , Organic contact allergens like 2, 4, 6-trinitrochlorobenezene (TNCB) induce hyaluronic acid (HA) degradation and ATP release from stressed and damaged cells resulting in an inflammatory response in the skin. Induction of skin inflammation by contact allergens is a highly regulated response, and involves TLR2/4, P2X7 and IL-1R receptors stimulated by HA, ATP and IL-1β respectively. Receptor-ligand interactions induce downstream signalling resulting in the activation of the innate immune system, leading to skin inflammation. ADDIN EN.CITE 133-135 Furthermore, generation of ROS by contact allergens is a well characterised pathway for the activation of the innate immune system. A major issue with the exploration of the immune system in DHRs is the limited number examples of established animal models that closely reflect the human disease. Until now, the nevirapine-induced skin rash observed in female Norway rats is the only model that has been shown to have close similarities with nevirapone-induced skin rash in humans. ADDIN EN.CITE , Moreover, in vitro models of drug or chemical immunogenicity that are being developed (see below) do not include the tissue-derived signals responsible for activation of dendritic cells. 
In recent years it has been shown that dysregulated co-inhibitory receptor signalling can propagate autoimmunity, ADDIN EN.CITE 138-144 and that blocking these pathways in cancer models can significantly enhance functional T-cell responses. ADDIN EN.CITE 145-147 Recently, a synergistic interaction of HLA-alleles and polymorphic variants of the co-inhibitory receptor CTLA4 has been shown to predispose individuals to the T-cell mediated disorder Grave’s Disease.148 Thus, it is conceivable that dysregulated immune regulation pathways may manipulate the threshold of T-cell activation to such an extent that they enhance a patient’s susceptibility to drug hypersensitivity. Indeed we have reported an inhibitory role for the co-inhibitory Programmed Death-1 (PD-1) pathway during the priming of naïve T-cells to drug-antigens. ADDIN EN.CITE 149 Although PD-1 is a critical immune checkpoint, complex interplay between multiple pathways means that it is crucial to elucidate the role of multiple co-signalling pathways to effectively analyse the role of inhibitory signalling during T-cell activation. In this respect, Uetrecht and colleagues have shown that inhibition of immune tolerance can unmask drug-induced allergic hepatitis in animal models. ADDIN EN.CITE 150-152 Specifically, the amadiaquine-, isoniazid- and nevirapine-induced liver injury is potentiated following blackade of CTLA-4 and PD1 signalling   

THE CHEMISTRY OF DRUG MHC BINDING                    
The hapten hypothesis and the pharmacological interactions with immune receptors (p-i), well-established mechanisms of T-cell activation, are briefly discussed below. Tony Purcell (Monash University, Australia) was invited to the workshop to elaborate on the altered self-peptide repertoire concept, the most recently described mechanism of drug-specific immune activation, and to discuss the relevance of the individual pathways of drug-specific T-cell activation in the human disease.
The hapten hypothesis provided an initial explanation for how small molecule drugs overcame their native small and thus non-immunogenic size to induce immune-mediated reactions. This hypothesis proposed that immune stimulation occurred through the binding of drug antigen to protein to form a hapten-protein complex. The hypothesis was first conceived after the identification of a relationship between sensitisation potential of chemicals and the extent of protein binding and reported in the landmark paper of Landsteiner and Jacobs in 1935.153 This complex, now large enough to be recognised by circulating dendritic cells, is taken and processed by antigen presenting cells. The peptide products of processing are subsequently presented on the cell surface bound to MHC molecules, which TCRs on passing T-cells can recognise.154 A slightly different mechanism is needed for drugs which lack chemical reactivity but are metabolised to protein reactive substances. Thus, the term pro-hapten hypothesis was conceived. It is identical to the hapten hypothesis but it is a metabolite that binds covalently to protein and not the parent drug. 
Recent advances in mass spectrometry-based proteomics have allowed for characterisation and quantification of hapten-protein complexes formed by drugs or metabolites in great detail. The chemical nature, quantity, and exact location of haptens that bind to proteins have been extensively studied in vitro and in patients. Human serum albumin and haemoglobin have been identified as targets for numerous drugs (metabolites) including β-lactam antibiotics, ADDIN EN.CITE , phase I reactive drug metabolites such as quinone imines (acetaminophen and lapatinib)158 and epoxides (carbamazepine),159 phase II metabolites such as acyl glucuronides (diclofenac) ADDIN EN.CITE 160 and sulphates (nevirapine), ADDIN EN.CITE 156 and covalent inhibitors (neratinib). ADDIN EN.CITE 161 Other proteins such as cytochrome P450 and glutathione S-transferase pi in the liver and keratin in the skin are also potential targets for haptenation. Hapten-protein complexes have been detected within cells as well as cell culture medium, ADDIN EN.CITE , in tissues (skin and liver), ADDIN EN.CITE 164-166 and in patients taking therapeutic drugs. ADDIN EN.CITE ,,,,, Although much progress has been made in characterisation of hapten-protein complexes, for many drugs, the target proteins with respect to their location, the quantity, and in particular, their biological function in the immune system remain to be defined. Furthermore, the bona fide haptenated peptides that are presented on the surface of antigen presenting cells have not been characterized. Future research employing new proteomic technologies to identify these naturally processed immunogenic peptides will certainly provide affirmative evidence for the hapten hypothesis.
It has also been shown that parent drugs can directly activate T-cells by a non-covalent, reversible interaction with the MHC and/or TCR. This theory, the “pharmacological Interaction” or PI concept, states that a drug may directly bind to an antigen receptor, whether this is the TCR, MHC, or both to stimulate a T-cell response independent of antigen uptake and processing by dendritic cells. Figure 1 illustrates the main models of T-cell activation. Drugs such as SMX are able to stimulate TCR via this direct interaction as assessed by positive T-cell stimulation in the presence of fixed antigen presenting cells (to abolish antigen processing but allowing MHC-antigen binding).169 Further proof lies in the recognition that stimulation of T-cells by some drugs occurs within seconds, which is too quick for a protein adduct to have been engulfed, processed, and externally displayed. Importantly, the PI concept has originated exclusively from in vitro assessment of T-cells isolated from human patients and it is now imperative to put these findings in the context of the iatrogenic disease that has a delayed onset. 
It is generally thought that hapten and pro-hapten associated drugs stimulate a novel response and as such naïve T-cells are implicated; however, memory T-cells may be preferentially activated by drugs associated with the PI-concept.154 It is likely that PI-dependent T-cell activation only occurs on T-cells with low thresholds for activation.169 While this rapid activation of T-cells may at first appear contradictory to the delayed nature of T-cell hypersensitivity reactions, it is important to bear in mind that even the first contact between dendritic cells and T-cells occurs 3-15 hours after administration in vivo. Moreover, the activation of naïve CD4+ T-cells in vivo has been reported to require a minimal stimulation period of 6 hours before subsequent clonal expansion, with a sustained CD4+ response being dependent on additional signals produced by dendritic cells which occur more than 24 hours after the initial exposure. Moreover, these events only represent the beginning of the T-cell response which requires time-consuming events such as gene activation and the production of cytokines. Indeed, these late signals appear to be important for distinct functions of the response that result in the development of clinically distinct DHRs. ADDIN EN.CITE 170-173 
The altered-self peptide hypothesis was put forward in 2012 to explain the mechanism of abacavir hypersensitivity. ADDIN EN.CITE 32 About 5-7% of abacavir-exposed patients present with hypersensitivity characterised by fever, rash, malaise, nausea, vomiting and diarrhoea. GWAS demonstrated that 100% of patients that experienced abacavir hypersensitivity were positive for the MHC class I allele HLA-B*57:01. ADDIN EN.CITE 174 Tissue injury is thought to be CD8+ T- cell mediated since abacavir-specific CD8+ T-cells have been isolated from hypersensitive patients and generated from drug-naïve donors expressing HLA-B*57:01. ADDIN EN.CITE , T-cell activation involves abacavir-dependent alteration of the repertoire of self-peptide presented to T-cells in the context of HLA-B*57:01. Abacavir was found to interact specifically but non-covalently with the F-pocket of the antigen binding cleft of HLA-B*57:01. Purcell and his colleagues have been successful in isolating and identifying peptides bound to HLA-B*57:01 using the CIR cell line but also in delineating the structural basis of the abacavir hypersensitivity allele specificity. Their more recent research has looked at the kinetics of abacavir-induced changes in the self-peptide repertoire. Such elegant experiments have the potential to provide valuable information concerning specific peptides that activate T-cells responsible for abacavir hypersensitivity.
Although drugs such as carbamazepine (HLA-B*15:02 and A*31:01) and allopurinol (HLA-B*58:01) interact with proteins encoded by specific HLA alleles, the ability of these drugs to alter the immunopeptidome and trigger a hypersensitivity reaction has not been demonstrated conclusively. Interestingly, Metushi et al have shown that acyclovir interacts with HLA-B*57:01 in a similar manner to abacavir but does not induce hypersensitivity reactions. ADDIN EN.CITE 177 They demonstrated that the changes in peptide affinity in the presence of acyclovir were 2-5- fold compared to the 1000-fold change observed with abacavir. Could the induction of hypersensitivity be regulated by a defined threshold of altered-self peptides? The challenge and unmet need remains the development of high throughput assays capable of screening drugs and their metabolite(s) for the potential to alter the display of self-peptides by MHC molecules. 

Moving Forward:
Critical questions: (1) how do the cellular components and tissue-derived signals vary in different tissues as a result of drug/chemical-induced cell stress? (2) Do these differences explain why some drugs selectively target certain organs? (2) Are there organ-specific thresholds for signals required to drive inflammatory responses (3) what is the correlation between the nature of the immune effector mechanisms and the nature/intensity of the hypersensitivity reactions induced?  
















Figure 1: Models of TCR activation by drug or chemical antigens. (A) The hapten hypothesis states that a drug binds to protein to form a hapten and become recognisably immunogenic. The hapten is then internalised and processed by antigen presenting cells to form antigenic peptide fragments which are subsequently loaded onto MHC molecules (covalent binding) and presented at the cell surface to passing T-cells. (B) The PI concept states that chemically inert parent drugs or chemicals can interact (non-covalently) directly with the MHC-TCR without the need for protein binding or antigen processing. (C) The altered peptide concept states that a drug may bind to the MHC-peptide complex in such a way that altered self-peptides represent an antigenic signal. This may refer to binding of drug (i) to HLA outside the peptide binding groove, (ii) to HLA in the peptide binding groove, or (iii) directly to the self-presented peptide. Peptide A = normal self-peptide; peptide B = altered self-peptide.


TOWARDS THE DEVELOPMENT OF PREDICTIVE ASSAYS    
In vitro approaches to predict drug immunogenicity 
A meeting was held in Rome in 2009 to discuss T-cell recognition of chemicals, protein allergens and drugs with an overall aim of moving towards the development of in vitro assays. The status of the field and outcomes of the meeting were summarized in an article by Martin et al. ADDIN EN.CITE 178 The need to develop in vitro assays utilising human cells to predict immunogenicity, and to move away from animal-based models was based on ethical and moral obligations, and the subsequent legal enforcement of restricted animal use for drug testing and the assessment of cosmetic sensitisation potential (7th amendment of the EU cosmetics directive [March 2009]). The article by Martin et al highlights key developments allowing for the emergence of ‘state-of-the-art’ T-cell assays including the utilisation of magnetic beads and flow cytometry to isolate pure cell populations, the identification of further T-cell activation markers as readouts and the identification of optimised T-cell culture conditions. Such pure T-cell populations allow for the removal of immunosuppressive Tregs which would otherwise limit the detection of effector T-cell responses. ADDIN EN.CITE , Moreover, the authors highlighted the importance of advanced in vitro culture techniques for dendritic cells as the availability of well-characterized non-tolerogenic dendritic cells is important for the detection of primary T-cell responses to drugs and chemicals. The authors proposed that functional maturation of dendritic cells by LPS and TNF-α should be performed to surpass the need for specific tissue-derived danger signals received in vivo. ADDIN EN.CITE 178 Indeed, a number of groups have now described the priming of naïve T-cells sorted from human donors to drugs and chemicals, with mature dendritic cells. It is these assays which are now being utilised and developed to investigate the intrinsic immunogenicity of drugs and chemicals.
Dean Naisbitt (The University of Liverpool) discussed the priming of human naïve T-cells to drugs using cells from a bank of 1000 HLA-typed healthy volunteers. The ready supply of PBMCs from healthy donors is critical to study the immune pathogenesis of the increasing number of HLA allele-restricted forms of hypersensitivity. ADDIN EN.CITE 180-183 Naisbitt discussed the applicability domain of existing T-cell assays. It was agreed that T-cell priming assays in their current form are useful to (1) study mechanisms when a problem has been identified in the clinic and (2) investigate structurally related possibly “second-in-line compounds.” However, they could not be used to list compounds in terms of immunogenic potency simply because the sensitivity and specificity of the assay had not been validated. The failure to solubilise certain compounds in a suitable form for the T-cell assay limits its usefulness. Furthermore, the absence of known synthetic drug metabolites and/or relevant carrier proteins for reactive metabolites restricts the interpretation of a negative result with a parent drug.  
Despite these limitations, in vitro T-cell priming assays such as that used in Liverpool ADDIN EN.CITE 180 have greatly enhanced our understanding of the origins of drug antigen-specific T-cell activation. Focussing on the model antigen, SMX, it has been possible to study (1) mechanisms of drug-specific T-cell priming, (2) the stress-signalling pathways involved in T-cell activation and (3) immune regulation. The oxidative metabolism of SMX has been fully-characterized, and its synthetic reactive metabolite SMX-NO is commercially available for functional assays. ADDIN EN.CITE 184 SMX and SMX-NO can stimulate primed naïve T-cells to proliferate and to secrete cytokines such as IFN-, IL-5 and IL-13. Moreover it is possible to clone drug- and drug metabolite-specific T-cells from the priming assay and what is observed is essentially no cross-reactivity (i.e., SMX-reactive T-cells are not activated with the nitroso metabolite and vice-versa). As discussed above, it has been hypothesized that drugs which activate T-cells via a PI mechanism might preferentially activate memory T-cells. Thus, the T-cell assay has been modified to utilize purified memory T-cells from healthy donors. Somewhat surprisingly, SMX and SMX-NO were able to stimulate memory CD4+ T-cells to proliferate and secrete cytokines. Although an array of co-stimulatory and co-inhibitory proteins are expressed on the surface of DCs, it is still unclear how the signalling of individual molecules act to regulate drug-specific T-cell priming. Naisbitt partly addressed this point by showing preliminary data using specific inhibitory antibodies alone or in combination ADDIN EN.CITE 8. The stepwise inhibition of immune regulation seemed to represent a promising technique to enhance the detection of a drug-specific immune response. Finally, immune regulation might then be fed back into the priming assay to determine whether responses in individual patients are differentially regulated. The T-cell priming assay has now been applied successfully to investigate HLA allele-restricted forms of hypersensitivity with some success. For 7 drugs highlighted in Figure 2 it has been possible to prime naïve T-cells or activate pre-existing memory T-cells from healthy volunteers who carry HLA risk alleles. In most cases, T-cells have been cloned from the priming assay and characterized in terms of (1) antigen specificity, (2) HLA restriction, (3) cellular phenotype and (4) mechanisms of cytotoxicity.

Figure 2 Definition of the causal alleles and immune responses associated with reactions targeting skin and liver


Integration of tissue cells into in vitro approaches to predict drug immunogenicity 
Shaheda Ahmed (Alcyomics Limited) discussed the technologies available to the pharmaceutical, biotechnology, cosmetic and chemical industries to assess immunogenicity of drug/metabolites and chemical compounds. The use of human in vitro models such as the SkimuneTM have the ability to identify the potential for monoclonal antibodies, protein therapeutic immunodulators and small chemical molecules to induce cutaneous hypersensitivity reactions. The test compound is incubated with dendritic cells, derived from CD14+ monocytes isolated from PBMCs of a healthy volunteer. Dendritic cell exposure to antigens induces T-cell maturation, proliferation and cytokine secretion. ADDIN EN.CITE 185 Skin samples obtained from the same volunteer are then incorporated into the assay followed by histological analysis. In vitro tissue damage is graded from I-IV as described by Lerner et al ADDIN EN.CITE 186 as a marker of immune sensitisation and cytotoxicity. Data obtained from this human in vitro system correlates well with the disease and can be used to predict clinical outcomes. These data also correlates well with T-cell proliferation and cytokine release assays, which can be used as sensitive screening tools for predicting potential reactions. Ahmed stressed that that this model also has the potential to predict rare reactions during clinical trials such as the cytokine storm associated with TGN1412 IN 2006. ADDIN EN.CITE 187 However, interestingly, the SkimuneTM
Test shows a positive response for drugs which show adverse reactions to be associated with a specific HLA allele. An example of this is abacavir, which despite the association of hypersensitivity reactions to the MHC class I allele HLA-B*57:01, shows a positive response in the SkimuneTM tests. This goes against clinical evidence and studies with T-cells from HLA-B*57:01 positive and negative donors and suggests HLA is not imperative to the induction of skin injury.

Moving Forward:
Critical questions: (1) Why is the skin the site of most hypersensitivity reactions when most drug metabolism does not occur in the skin? (2) What are the mechanisms of viral reactivation in DRESS since this can be triggered by different drugs? (3) Is viral reactivation in DRESS critical for tissue damage? (4) How does the nature of the immune microenvironment in the skin change over time? (5) Do investigations using immune cells in the blood accurately reflect what is happening in the skin?


In vivo approaches to predict drug immunogenicity
Some of the challenges associated with the development of animal models of drug hypersensitivity include incomplete understanding of the mechanisms driving the reactions, the relative roles of different mechanisms and risk factors, and the rarity of observing these reactions during early toxicity studies. Jessica Whritenour (Pfizer) and her colleagues have developed a mouse allergy model based on lymph node proliferation. ADDIN EN.CITE ,  The assay involves subcutaneous administration of test compounds once daily for 3 days followed by a 2 day rest and then assessment of lymph node cellularity by flow cytometry on day 6. A stimulation index [mean total cell number (treatment group)/mean total cell number (vehicle group)] ≥ 2.5 is considered a positive response. Using positive and negative control drugs (defined as such by the occurrence of hypersensitivity reactions in the clinic), the potential of a test compound to induce hypersensitivity reactions can be assessed. Positive control drugs were shown to increase the number of immune cells (T- and B-cells) in draining lymph nodes and induce changes in the expression of the homing receptors CD62L and CCR7 on T-cells. Low bulk requirement, high throughput relative to other mouse models and an absence of radioactive endpoints are advantages of the mouse allergy model. However, the obvious limitations are lack of insight on the immunological mechanism induced by the compounds and restriction of the model to subcutaneous injection. Furthermore, Whritenour highlighted that certain compounds had a tendency to produce false positive and false negative results. While this model may be used to help de-risk backup molecules (once an issue has been identified), the translation of a positive response in the model to human risk is unknown. Therefore this assay requires further refinement and validation to prevent pharmaceutical companies from discarding potential candidate drugs at an early stage of development.      

Expert opinion and conclusion
In vitro T-cell priming assays are now established and used by several groups to explore mechanisms of T-cell activation by drugs/chemicals. However, at the moment, such assays cannot be used by the pharmaceutical industry to screen, ab initio, the potential that individual compounds will cause DHRs when administered widely to humans. One of the critical action points discussed at the meeting highlighted the urgent need to develop high throughput assays capable of predicting potential HLA-associated DHRs. However, the demands of adapting an in vitro system used in a research setting into a screening assay for industry are considerable. 
Following this workshop, it is believed that a number of groups have made important advances in their assays to investigate drug hypersensitivity, which will potentially form part of the agenda for the next meeting. At the CDSS we have challenged ourselves to identify screening strategies where we can use an established biobank of PBMCs isolated from 1000 HLA-typed volunteers. The current form of the T-cell priming assay can only look at a single HLA risk allele, is labour intensive, uses different plate formats, has multiple readouts and takes 3-4 weeks to run. A screening assay would need to include multiple donors with and without several different HLA risk alleles and be simplified to run on a single plate format using a single readout. In a screening assay for HLA Class I risk alleles, we could potentially include 3 donors with B*13:01, 2 donors with A*33:03 and B*15:02 and a minimum of 5 donors for the remaining alleles (A*02:06, A*31:01, A*68:01, B*35:05, B*44:03, B*56:02, B*57:01, B*58:01 and C*04:01). Five donors without the HLA risk alleles would then be selected as negative controls and a unique donor would be used as a positive control. We are currently developing this screening assay and our initial efforts have concentrated on optimising assay conditions using SMX-NO as a test compound. Next the sensitivity of the assay will be explored using blocking antibodies against co-inhibitory molecules of T-cell activation such as CTLA4, PD-1 and Tim-3 before testing the screening assay with a set of test compounds known to cause hypersensitivity.
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Philippe Musette MD, PhD is professor of Dermatology at Rouen University Hospital and is the director of a team focussed on immunodermatology and rheumatology  at the INSERM.  His research topics include the role of viral reactivation in severe cutaneous side effects and the immune mechanisms of auto-immune bullous diseases and he conducts innovative clinical trials in immunodermatology.

Dr Alan Norris, a pharmacologist, is the Industry Programme Manager for the MRC Centre for Drug Safety Science with responsibility for managing interactions with industry partners.  Prior to this he was Director for Strategic Alliances at Novartis Institutes for Biomedical Sciences with responsibility for all global business development activities for the company in the gastrointestinal and respiratory fields from pre-clinical stage to proof of concept in man.  

Dr Lee Faulkner is a post-doctoral researcher at the MRC Centre for Drug Safety Science, The University of Liverpool. Her current research interest is the development of T-cell assays to predict the immunogenicity of drugs and chemicals. Previously, she has worked on the role of T cells in toxic shock and nasopharyngeal carcinoma. 

Dr Monday Ogese graduated with bachelors in Pharmacy from the University of Jos, Nigeria in 2005. In 2009, he enrolled for his postgraduate studies at the University of Liverpool where he obtained a Masters of Research and PhD in Pharmacology. His PhD research focused on “antigenic determinants of drug hypersensitivity reactions”. He is currently a postdoctoral fellow with AstraZeneca, UK, and his research interest revolves around understanding the molecular pathomechanism of adverse drug reactions targeting the liver.

Kevin Park is currently Professor of Pharmacology and Head of the Institute of Translational Medicine at the University of Liverpool.  He is a Fellow of the Royal College of Physicians and a Fellow of the Academy of Medical Sciences. The over-riding theme of his work is bringing “molecule–to-man” and back again, to enable the prediction of adverse drug reactions based on the chemical structure of the drug and the identification of susceptible individuals. This work has been expanded by using pharmacogenomics and toxicogenomics to link findings in patients to the chemical structure of the drug. 

Professor Sir Munir Pirmohamed is currently David Weatherall Chair in Medicine at the University of Liverpool, and a Consultant Physician at the Royal Liverpool University Hospital.  He is also the Associate Executive Pro Vice Chancellor for Clinical Research for the Faculty of Health and Life Sciences.  He holds the only NHS Chair of Pharmacogenetics in the UK, and is Director of the MRC Centre for Drug Safety Sciences, Director of the Wolfson Centre for Personalised Medicine and Executive Director, Liverpool Health Partners.   His research focuses on personalised medicine in order to optimise drug efficacy and minimise toxicity.

Tony Purcell is a Professorial Fellow and Deputy Head Department of Biochemistry at Monash University. He is currently an executive committee member of the Australasian Proteomics Society and the Australasian Peptide Society and was recently elected to the Human Proteome Organisation Council. His laboratory focusses on how the diverse array of peptides presented to the immune system, the immunopeptidome, is influenced by infection, inflammation and the environment. He has made important contributions to understanding the role of antigen presentation, including the characterizing peptide epitopes involved in T cell recognition, in several autoimmune diseases, drug hypersensitivity, cancer and infectious diseases.
Dr Colin Spraggs (Target Sciences, GlaxoSmithKline, UK) has broad experience in drug discovery and development as a pharmacologist, clinical development leader and geneticist.  His recent work has utilised pharmacogenetics to identify and characterise the association of a specific HLA allele (DRB1*07:01) with liver injury caused by lapatinib and resulted in validated HLA biomarker data inclusion in the Tykerb/Tyverb product label.  His current research utilises human genomic data to identify and select novel disease targets as potential medicines.

Dr Jessica Whritenour is a Senior Principal Scientist in the Immunotoxicology group within the department of Drug Safety Research and Development at Pfizer Inc.  She has a special interest in understanding mechanisms of drug hypersensitivity reactions, and in the development of predictive and diagnostic tools that can be used during drug development.
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